Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 24, 2019
A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cellsIsabella Orienti, Valentina Salvati, Giovanni Sette, et al.
Blood Advances|September 11, 2020
Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell deathDebora Soncini, Paola Minetto, Claudia Martinuzzi, et al.
Cell Death & Disease|July 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomasMichela Chiappa, Alessandra Decio, Luca Guarrera, et al.
Pharmaceutics|July 30, 2025
Pharmacokinetics of Pegaspargase with a Limited Sampling Strategy for Asparaginase Activity Monitoring in Children with Acute Lymphoblastic LeukemiaCristina Matteo, Antonella Colombini, Marta Cancelliere, et al.
The Lancet. Oncology|September 16, 2018
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma GroupGiovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, et al.
Cancer Cell|February 16, 2013
Role of macrophage targeting in the antitumor activity of trabectedinGiovanni Germano, Roberta Frapolli, Cristina Belgiovine, et al.
Therapeutic Advances in Medical Oncology|July 5, 2022
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)Charlotte I Stroes, Sandor Schokker, Mohammed Khurshed, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Pageof 10